Trial · NCT07328425
Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS
NCT07328425, Phase 2, Recruiting, Italian Sarcoma Group
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS. Trials, record NCT07328425. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07328425
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS
- NCT number
- NCT07328425
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Italian Sarcoma Group
- Conditions
- Desmoplastic Small Round Cell Tumor
- Interventions
- Lurbinectedin, Irinotecan
- First posted
- 2026-01-09
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall tumour Response Rate (ORR), according to RECIST v 1.1 | Week 6, week 12, week 18, week 30, week 42, week 54, week 66, week 78, week 90, week 102 and until progression | Overall tumour Response Rate (ORR), according to RECIST v 1.1 |
| Secondary | Overall Survival (OS) | From date of study therapy start until the date of death from any cause, assessed up to 60 months | Overall Survival (OS) |
| Secondary | Progression Free Survival (PFS) | From date of study therapy start until first documented progression or date of death from any cause, whichever came first, assessed up to 60 months | Progression Free Survival (PFS) |
| Secondary | Duration of Response (DoR) | From date of study therapy start until first documented assessment without progression or date of death from any cause, whichever came first, assessed up to 60 months | Duration of Response (DoR) |
| Secondary | Adverse events and Serious adverse event (according to CTC-AE v.5) | After initiation of study treatments(s), all adverse events will be reported until 30 days after the final dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurs first. | Adverse events and Serious adverse event (according to CTC-AE v.5) |
| Secondary | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Screening, cycle1 day1 (each cycle is 21 days), cycle2 day1, End Of Treatment visit (performed 30 days after the last study drug administration), at follow-up visits performed at months 6, 12, 18 and 24 after the last study drug administration | The EORTC QLQ-C30 is a validated 30-item questionnaire assessing health-related quality of life in cancer patients. Scores are linearly transformed to a 0 to 100 scale. For the Global Health Status/Quality of Life and functional scales (physical, role, emotional, cognitive, and social functioning), higher scores indicate better quality of life or functioning. For the symptom scales and single-item symptom measures, higher scores indicate greater symptom severity (worse outcome). |
| Secondary | Brief Inventory Pain questionnaire | Screening, cycle1 day1 (each cycle is 21 days), cycle2 day1, End Of Treatment visit (performed 30 days after the last study drug administration), at follow-up visits performed at months 6, 12, 18 and 24 after the last study drug administration | Brief Inventory Pain questionnaire |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers41
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07328425
GET https://conductscience.org/api/trials/v1/NCT07328425/papers?page=2